hydrogen has been researched along with Degenerative Diseases, Central Nervous System in 13 studies
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.
dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| " First, no dose-response effect is observed." | 2.48 | Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases. ( Ichihara, M; Ito, M; Ohno, K, 2012) |
| "Hydrogen Therapy (HT) has gained scientists' attention with the proven clinical ability to attenuate chronic inflammation, diminish oxidative stress, restrict apoptosis, minimize cellular injury, and refine tissue functioning." | 1.72 | Narrative on Hydrogen Therapy and its Clinical Applications: Safety and Efficacy. ( Ahmad, A; Ahmed, N; Baig, AA; Bilal, M; Chopra, H; Hassan, M; Hussain, M; Kamal, MA; Khaliq, M; Putnala, SK; Rachamalla, M; Saeed, MU; Tahir, Z, 2022) |
| " Here, we show that drinking H(2)-containing water significantly reduced the loss of dopaminergic neurons in PD model mice using both acute and chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.35 | Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. ( Fujita, K; Katafuchi, T; Kido, MA; Nakabeppu, Y; Noda, M; Ohno, M; Sakumi, K; Seike, T; Takaki, A; Tanaka, Y; Yamada, H; Yamaguchi, H; Yamakawa, Y; Yutsudo, N, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 6 (46.15) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Z | 1 |
| Zhang, J | 1 |
| Zhang, Y | 1 |
| Ahmad, A | 1 |
| Baig, AA | 1 |
| Hussain, M | 1 |
| Saeed, MU | 1 |
| Bilal, M | 1 |
| Ahmed, N | 1 |
| Chopra, H | 1 |
| Hassan, M | 1 |
| Rachamalla, M | 1 |
| Putnala, SK | 1 |
| Khaliq, M | 1 |
| Tahir, Z | 1 |
| Kamal, MA | 1 |
| Qi, B | 1 |
| Song, Y | 1 |
| Chen, C | 1 |
| Zhao, L | 1 |
| Ma, W | 1 |
| Meng, S | 1 |
| Zhuang, X | 1 |
| Lin, H | 1 |
| Liang, J | 1 |
| Cui, Y | 1 |
| Xie, K | 1 |
| Chow, V | 1 |
| Wolf, E | 1 |
| Lento, C | 1 |
| Wilson, DJ | 1 |
| Noda, M | 3 |
| Liu, J | 1 |
| Long, J | 1 |
| Nishimaki, K | 1 |
| Asada, T | 1 |
| Ohsawa, I | 1 |
| Nakajima, E | 1 |
| Ikejima, C | 1 |
| Yokota, T | 1 |
| Kamimura, N | 1 |
| Ohta, S | 2 |
| Uemura, Y | 1 |
| Yoshii, Y | 1 |
| Horita, T | 1 |
| Takemi, S | 1 |
| Sakata, I | 1 |
| Sakai, T | 1 |
| Fujita, K | 1 |
| Seike, T | 1 |
| Yutsudo, N | 1 |
| Ohno, M | 1 |
| Yamada, H | 1 |
| Yamaguchi, H | 1 |
| Sakumi, K | 1 |
| Yamakawa, Y | 1 |
| Kido, MA | 1 |
| Takaki, A | 1 |
| Katafuchi, T | 1 |
| Tanaka, Y | 1 |
| Nakabeppu, Y | 1 |
| Ohno, K | 1 |
| Ito, M | 2 |
| Ichihara, M | 1 |
| Buck, HM | 1 |
| Terakawa, H | 1 |
| Abe, K | 1 |
| Watanabe, Y | 1 |
| Nakamura, M | 1 |
| Fujita, N | 1 |
| Hirabuki, N | 1 |
| Yanagihara, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02830854] | Phase 3 | 13 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| [NCT01759498] | Phase 2 | 36 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for hydrogen and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases.
Topics: Antioxidants; Cellular Senescence; Humans; Hydrogen; Neurodegenerative Diseases | 2022 |
Developments in rapid hydrogen-deuterium exchange methods.
Topics: Deuterium; Deuterium Exchange Measurement; Humans; Hydrogen; Intrinsically Disordered Proteins; Neur | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Circulating messenger for neuroprotection induced by molecular hydrogen.
Topics: Animals; Blood-Brain Barrier; Disease Models, Animal; Drinking; Gastric Mucosa; Ghrelin; Humans; Hyd | 2019 |
[Initiation, development and potential of hydrogen medicine: Toward therapeutic and preventive applications of molecular hydrogen against a variety of diseases].
Topics: Animals; Antioxidants; Gene Expression; Humans; Hydrogen; Neurodegenerative Diseases; Oxidative Stre | 2015 |
Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases.
Topics: Animals; Brain Diseases; Disease Models, Animal; Gases; Humans; Hydrogen; Metabolic Diseases; Neurod | 2012 |
Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases.
Topics: Animals; Brain Diseases; Disease Models, Animal; Gases; Humans; Hydrogen; Metabolic Diseases; Neurod | 2012 |
Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases.
Topics: Animals; Brain Diseases; Disease Models, Animal; Gases; Humans; Hydrogen; Metabolic Diseases; Neurod | 2012 |
Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases.
Topics: Animals; Brain Diseases; Disease Models, Animal; Gases; Humans; Hydrogen; Metabolic Diseases; Neurod | 2012 |
2 trials available for hydrogen and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment.
Topics: Administration, Oral; Aged; Aldehyde Dehydrogenase, Mitochondrial; Animals; Antioxidants; Apolipopro | 2018 |
6 other studies available for hydrogen and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Narrative on Hydrogen Therapy and its Clinical Applications: Safety and Efficacy.
Topics: Apoptosis; Humans; Hydrogen; Inflammation; Neurodegenerative Diseases; Oxidative Stress | 2022 |
Molecular hydrogen attenuates sepsis-induced cognitive dysfunction through regulation of tau phosphorylation.
Topics: Animals; Cognitive Dysfunction; Hippocampus; Hydrogen; Male; Mice; Mice, Inbred C57BL; Neurodegenera | 2023 |
Neuroprotective and Preventative Effects of Molecular Hydrogen.
Topics: Animals; Female; Hydrogen; Mice; Neurodegenerative Diseases; Neuroprotection; Neuroprotective Agents | 2021 |
Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Hydrogen; L | 2009 |
The role of the carboxamide group in nicotinamide adenine dinucleotide in relation to hydride transfer: the reduced form of the dinucleotide as remedy in the modulation of neurotransmission.
Topics: Adenine Nucleotides; Amides; Animals; Carbon; Dinucleoside Phosphates; Humans; Hydrogen; Kinetics; M | 2005 |
Proton magnetic resonance spectroscopy (1H MRS) in patients with sporadic cerebellar degeneration.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Cerebellar Diseases; Cerebellum; Choline; Creatine; Disease Pro | 1999 |